Meeting
2016 ASCO Annual Meeting
Modeling the cost of immune checkpoint inhibitor-related toxicities.
Authors
Neil Thomas Mason
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Neil Thomas Mason , Nikhil I. Khushalani , Jeffrey S. Weber , Scott Joseph Antonia , Howard L. McLeod
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality of Care
Track
Health Services Research and Quality of Care
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 34, 2016 (suppl; abstr 6627)
DOI
10.1200/JCO.2016.34.15_suppl.6627
Abstract #
6627
Poster Bd #
109
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2019 ASCO Annual Meeting
A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated Classic Kaposi sarcoma (CKS).
First Author: Alona Zer
Poster
2019 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.
First Author: Emilia Nan Tie
Poster
2023 ASCO Annual Meeting
Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.
First Author: Scott N. Gettinger